DOCSLIB.ORG

Book of Suicide Methods for a Quick and Secure Departure from Life

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Book of Suicide Methods for a Quick and Secure Departure from Life book of suicide methods for a quick and secure departure from life part 1-30, some version of jak się zab ić wie brin gt man sich um come si suicida как совершать с амоубийств́ zěnme zìshā (怎么自杀, how to commit s uicide) this pdf was first uploaded the 5th of november 2013, is free to read and free to redistribute as a non-commercial e-book or text file of some other sort, under the terms of CC BY-NC-ND written by Nada Alleen version 1.03 (6th of november 2013) added part 011-013, changed the front page a bit, and made some small amendments to 006 + 009. version 1.07 (7th of november 2013) added part 014-017, and digitalis to 006 and 010. version 1.13 (8th of november 2013) added part 018-023, the average lethal dose of HCN to 003, and the Sophocles quote. version 1.14 (9th of march 2014) united 003 with 009, in place of the appleseeds method there's now the methanol intoxication on position 003. toxalbumins have been included into 011. and the Evan Harris Walker quote was put at the very beginning of the preface. a nap in the bath (015) has been inserted between 014 and the former 015. version 1.15 (31st of march 2014) included nux vomica into 018 and added method 025. version 1.16 (3rd of april 2014) extended 025 via an appendix, added a case example to 002, the Schopenhauer quote between 018 and 019, and finally, part 26. version 1.20 (6th of may 2014) presents 027 & 028. 008 has been relocated to 029. "Jefferson's recommendation" now sits in its former place. Szasz's & Reznor's quote has been added to the introduction. amanita muscaria has been added to 022. the car crash is now part of 002, which has been renamed to "blunt force trauma" (formerly: "overcoming the fear of heights"). savin oil has been added to 020. 007 has been rewritten. bitter apple has been added to 009. 018 has been extended. it now includes nicotiana tabacum & gelsemium sempervirens & euonymus species & myrtus communis. 015 has been trimmed to the most essential. 004 now carries the tool quote as foreword. what happens when you survive and end up in an emergency room is the topic of the new „interceptive“. then, following new quotes act as interludes: the one by Leo Tolstoy, by Horace McCoy, the 2 Ligotti quotes. the one from Strahan's book, the one by Jesus, by Pavese, by zralytylen, by Voltaire, by Bradley and the 2 by Szasz. all this is followed and concluded by method 030. and this in turn is concluded by the rewritten conclusion. as well as appendix A & B. content overview introduction part 0 001 partial suspension hanging, preceded by drinking... 001 blunt force trauma 002 drinking, preceded by drinking... 005 suicide by snake bite 006 kissing your dearest ones yourself goodbye 008 breaking (hemlock & wolf's bane) for a cup of tea 009 dieting on salads 012 Jefferson's recommendation 014 giving in to bitterness 017 fasting yourself to death 019 eating from the tree of knowledge 020 exchanging headache for a headache 022 combining over-hydration with hypervitaminosis A 024 a nap in the cold 027 a nap in the bath 028 interceptive il dolce vino 029 metal 030 les autres fleurs du mal 032 “i ain't givin you no golden shot" 037 protective parathion/savin hand lotion 040 impromptu railway promenade 042 pizza ai funghi 043 antitussives that toss away your tussis. for good 044 letting things end this way. in tears 045 SSRI * MAOI = peace of mind² 047 pressants, pressants, et al. 058 over-the-counter sleep aids 065 zhōng yī (中医, traditional chinese medicine) 071 mixing 10 capsules of tramadol with... 078 "non dolet, Paete!" 078 conclusion chemical ways to achieve unconsciousness, appendix A 081 natural ways to achieve unconsciousness, appendix B 083 introduction „think of the plans we make for our lives […] our plans feed our daydreams. we stare out windows imagining loves fulfilled, futures blessed with success, riches, fame, recognition, and respect. we hope and we build ever more elaborate plans to hide our disillusionment as each hope slips away. then one day we awaken to find ourselves buying lottery tickets to patch these ludicrous fantasies together as they turn to nothing“ -Evan Harris Walker, from 'the physics of consciousness', p. 2 things will never get any better. you can exert yourself as much as you like, and for a while it might look like there's a way out of where you were put into and want to get out of, in the end you'll come to find that there never was any opportunity to grasp at and hold onto delight and ecstasy, blithe sublimitiy, self-fulfillment and acknowledgement, those lavish luxuries that were held just above your head, seemingly within reach, in actuality, though, not. you will grasp at nothing. that's how things are supposed to be. try to defy this and "the clouds will part and the sky cracks open and god himself will reach his fucking arm through, just to push you down, just to hold you down. stuck in this hole with the shit and the piss and it's hard to believe it could come down to this. back at the beginning. sinking. spinning" -Trent Reznor, "the wretched" i guess a mixture of some barbiturate + some antiemetic or other kind of substance that prevents vomiting, like it's being used in Switzerland and Belgium and the Netherlands for euthanizing people, is not up for debate anymore. "in the good old days you could get barbiturates. now of course you can no longer get barbiturates, because barbiturates are very useful. besides sleeping for one night you can sleep forever" -Thomas Szasz, speech from 1994, "on socialism in health care", https://www.youtube.com/watch? v=FC9r3Gs8XuU but there's other ways that look promising and are within many people's (?) reach. here are the methods that maybe may be considered worth considering. part 0 going to work on a sunday because, as the bible says, "you shall keep the Sabbath, because it is holy for you. Everyone who profanes it shall be put to death" -Exodus 31:14 "for six days shall work be done, but the seventh day is a Sabbath of solemn rest, holy to the Lord. whoever does any work on the Sabbath shall be put to death" -Exodus 31:15 . okay, now let's be serious. part 1 partial suspension hanging, preceded by drinking... yourself unconscious. based on the results from my last attempt, 1 bottle of vodka (or a bit more), flushed down as quickly as possible, within a timespan of a few mins (one doesn't need to empty the bottle in one take, but one should not linger too long either) will make you pass out. so, if one is sitting upright and has a cord or cable or whatever wrapped around one's neck, and the other end fixed onto some spot above, maybe on a hook one 001 screwed into the ceiling a while ago, with a total length just about not long enough to let you bend forward anymore (or into any other direction), it means... you'd asphyxiate yourself the moment you drop off and your upper body (at least by a few centimeters) sinks down. according to Geo Stone's "suicide and attempted suicide" no more than 15 kg pulling on your ligature are needed to close your trachea and to cut you off from oxygen. part 2 blunt force trauma when seated in a car: what (minimum) speed leads to death when it drops to 0 in no more than a moment? in New Jersey, 2013, a 15 year old "crashed his car into another vehicle, killing him and two others, never even tapped the brake before the deadly wreck [...] investigators believe Srijan Saha [...] was driving his parents' 1995 Honda Civic at almost 100 mph when he veered into oncoming traffic and slammed into a car head-on" -http://www.nydailynews.com/news/national/new-jersey-teen-driving-100-mph-hit-brakes-suicidal-wreck- killed-3-report-article-1.1489496 also from 2013: "a crash in Graham that killed two men late Monday has been ruled a homicide-suicide, according to the Pierce County Sheriff’s department [...] both drivers were pronounced dead at the scene [...] investigators said the 19-year-old was speeding more than 100 miles per hour. when deputies went to notify the man’s family about the accident, they discovered a suicide note. “He’d left a suicide note saying he was going to drive his car 120 mph into a pole,” sheriff’s spokesman Ed Troyer said. “he got his car up to high speed to hit a pole and instead hit a truck, killing the other guy instantly.”" -http://blog.thenewstribune.com/crime/2013/05/28/two-men-killed-in-car-crash-in-graham/#storylink=cpy 002 100mph correspond to 160.93km/h successful crashes (leading to death) seem to be even possible at much lower speeds. Boone County, 2014: "investigators say a car that struck a tree Sunday morning, killing one current and one former student at Western Boone High School, was traveling at 65 mph just before the crash. the Boone County coroner determined that Jacob Shockley and Richard Penny, Jr. both died from blunt force trauma [...] medics declared both teens dead at the scene" -http://www.wthr.com/story/24987815/2014/03/16/boone-county-police-investigating-fatal-accident 65mph correspond to 104.61km/h a speed of around 100mph might the speed that leads to death when it drops to 0 in no more than a moment.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Protocol/Amendment No.: 252-10 a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combin
    Product: MK-3475 (SCH 900475), INCB024360 1 Protocol/Amendment No.: 252-10 (INCB 24360-301-10) / NCT02752074 THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. This study is co-funded by Incyte and MSD. Execution of Trial: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. One Merck Drive P.O. Box 100 Whitehouse Station, New Jersey, 08889-0100, U.S.A. Protocol-specific Contact information can be found in the Investigator Trial File Binder (or equivalent). Global Sponsor of the Study: Incyte Corporation (Referenced herein as Sponsor) 1801 Augustine Cut-Off Wilmington, Delaware, 19803, U.S.A TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK- 3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (KEYNOTE-252 / ECHO-301) IND NUMBER: 121,704 EudraCT NUMBER: 2015-004991-31 MK-3475-252-10 (INCB 24360-301-10) Final Protocol 18-May-2018 Confidential 04XN7M Product: MK-3475 (SCH 900475), INCB024360 2 Protocol/Amendment No.: 252-10 (INCB 24360-301-10) TABLE OF CONTENTS SUMMARY OF CHANGES.................................................................................................14 1.0 TRIAL SUMMARY...................................................................................................29 2.0 TRIAL DESIGN.........................................................................................................30
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Ayahuasca Characterization, Metabolism in Humans, And
    Louisiana State University LSU Digital Commons LSU Doctoral Dissertations Graduate School 2012 Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines Ethan Hamilton McIlhenny Louisiana State University and Agricultural and Mechanical College, [email protected] Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations Part of the Medicine and Health Sciences Commons Recommended Citation McIlhenny, Ethan Hamilton, "Ayahuasca characterization, metabolism in humans, and relevance to endogenous N,N- dimethyltryptamines" (2012). LSU Doctoral Dissertations. 2049. https://digitalcommons.lsu.edu/gradschool_dissertations/2049 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU Digital Commons. For more information, please [email protected]. AYAHUASCA CHARACTERIZATION, METABOLISM IN HUMANS, AND RELEVANCE TO ENDOGENOUS N,N-DIMETHYLTRYPTAMINES A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and School of Veterinary Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Interdepartmental Program in Veterinary Medical Sciences through the Department of Comparative Biomedical Sciences by Ethan Hamilton McIlhenny B.A., Skidmore College, 2006 M.S., Tulane University, 2008 August 2012 Acknowledgments Infinite thanks, appreciation, and gratitude to my mother Bonnie, father Chaffe, brother Matthew, grandmothers Virginia and Beverly, and to all my extended family, friends, and loved ones. Without your support and the visionary guidance of my friend and advisor Dr. Steven Barker, none of this work would have been possible. Special thanks to Dr.
    [Show full text]
  • Product Data Sheet
    Inhibitors Product Data Sheet Eprobemide • Agonists Cat. No.: HY-B1413 CAS No.: 87940-60-1 Molecular Formula: C₁₄H₁₉ClN₂O₂ • Molecular Weight: 282.77 Screening Libraries Target: Monoamine Oxidase Pathway: Neuronal Signaling Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : ≥ 125 mg/mL (442.06 mM) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.5364 mL 17.6822 mL 35.3644 mL Stock Solutions 5 mM 0.7073 mL 3.5364 mL 7.0729 mL 10 mM 0.3536 mL 1.7682 mL 3.5364 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.36 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.36 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.36 mM); Clear solution BIOLOGICAL ACTIVITY Description Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A. IC₅₀ & Target Monoamine oxidase A[1][2] In Vitro Eprobemide is a pharmaceutical drug that is used as an antidepressant. Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A that exhibits selective action on serotonin deamination[1][2]. Page 1 of 2 www.MedChemExpress.com MCE has not independently confirmed the accuracy of these methods.
    [Show full text]
  • Chemistry, Pharmacology and Medicinal Properties of Peganum Harmala L
    African Journal of Pharmacy and Pharmacology Vol. 6(22), pp. 1573-1580, 15 June, 2012 Available online at http://www.academicjournals.org/AJPP DOI: 10.5897/AJPP11.876 ISSN 1996-0816 ©2012 Academic Journals Review Chemistry, pharmacology and medicinal properties of Peganum harmala L. Jinous Asgarpanah and Fereshteh Ramezanloo Department of Pharmacognosy, Pharmaceutical Sciences Branch, Islamic Azad University (IAU), Tehran, Iran. Accepted 16 March, 2012 Peganum harmala L. is known as Syrian rue, Wild rue and Harmal. P. harmala extracts are considered important for drug development, because they are reported to have numerous pharmacological activities in the Middle East, especially in Iran and Egypt. For a long time P. harmala has been used in traditional medicines for the relief of pain and as an antiseptic agent. P. harmala also have antibacterial, antifungal, antiviral, antioxidant, antidiabetic, antitumor, antileishmanial, insecticidal and cytotoxic activities and hepatoprotective and antinociceptive effects. Harmaline, harmine, harmalol, harman, quinazoline derivatives, vasicine, vasicinone, anthroquinons and fixed oils are reported from seeds and roots of this plant. This plant is used as a medicine in Turkey, Syria, Iran, Pakistan, India, Egypt and Spain. This article presents comprehensive analyzed information on the botanical, chemical and pharmacological aspects of P. harmala. Key words: Peganum harmala, Zygophyllaceae, phytochemical, pharmacological properties. INTRODUCTION Peganum harmala commonly known as Syrian rue and many-branched stems may have a spread of four feet or Wild rue is a flowering plant and is widely distributed in more, the plant is rarely over two feet tall and generally the Central Asia, North Africa and Middle East. It has also appears round and bushy in habit.
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]
  • Attendee Guidelines
    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Implementation of Capillary Electromigrative Separation Techniques Coupled to Mass Spectrometry in Forensic and Biological Science
    CE-MS in Forensic and Biological Science CE-MS in Forensic Tjorben Nils Posch Tjorben Energie & Umwelt Energie & Environment Energy Implementation of capillary electromigrative separation techniques coupled to mass spectrometry in forensic and biological science Tjorben Nils Posch Energie & Umwelt / Energy & Environment Band/ Volume 228 ISBN 978-3-89336-987-4 228 Helmholtz Association Member of the Schriften des Forschungszentrums Jülich Reihe Energie & Umwelt / Energy & Environment Band / Volume 228 Forschungszentrum Jülich GmbH Zentralinstitut für Engineering, Elektronik und Analytik (ZEA) Analytik (ZEA-3) Implementation of capillary electromigrative separation techniques coupled to mass spectrometry in forensic and biological science Tjorben Nils Posch Schriften des Forschungszentrums Jülich Reihe Energie & Umwelt / Energy & Environment Band / Volume 228 ISSN 1866-1793 ISBN 978-3-89336-987-4 Bibliographic information published by the Deutsche Nationalbibliothek. The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at http://dnb.d-nb.de. Publisher and Forschungszentrum Jülich GmbH Distributor: Zentralbibliothek 52425 Jülich Tel: +49 2461 61-5368 Fax: +49 2461 61-6103 Email: [email protected] www.fz-juelich.de/zb Cover Design: Grafische Medien, Forschungszentrum Jülich GmbH Printer: Grafische Medien, Forschungszentrum Jülich GmbH Copyright: Forschungszentrum Jülich 2014 Schriften des Forschungszentrums Jülich Reihe Energie & Umwelt / Energy & Environment, Band / Volume 228 D 6 (Diss., Münster, Univ., 2014) ISSN 1866-1793 ISBN 978-3-89336-987-4 The complete volume is freely available on the Internet on the Jülicher Open Access Server (JUWEL) at www.fz-juelich.de/zb/juwel Neither this book nor any part of it may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.
    [Show full text]